Cemiplimab is a newer cancer treatment that has brought hope to patients with advanced skin and lung cancers It is part of an exciting group of drugs called immune checkpoint inhibitors, which help the body’s immune system fight cancer more effectively Cemiplimab is approved by the u.s Food and drug administration (fda) to treat advanced forms of skin cancers, including cutaneous squamous. The fda evaluated libtayo under priority review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in the treatment of serious conditions An additional regulatory application is also under review in the european union, with a decision expected by the first half of 2026.
WATCH
